Fang Liz Zhou (Fang L Zhou)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 15

Top Topics

Glycemic Control

Tyrosine Kinase

Cardiovascular Disease

Electronic Health Record

Top Venues

Diabetes, obesity & metabolism

Endocrinology, diabetes & metabolism

BMJ open diabetes research & care

This page only lists publications with an associated author ORCID identifier.

Publications

Angela Ibald-Mulli, Jochen Seufert, Julia M Hermann, Markus Laimer, Peter Bramlage, Alexandre Civet, Margot Blanchon, Simon Gosset, Alexandre Templier, W Dieter Paar, Fang Liz Zhou, Stefanie Lanzinger
Identification of Predictive Factors of Diabetic Ketoacidosis in Type 1 Diabetes Using a Subgroup Discovery Algorithm. Diabetes, obesity & metabolism (2023)
Stewart B Harris, Kamel Mohammedi, Monica Bertolini, John White, Valery Walker, Fang Liz Zhou, John E Anderson, Jochen Seufert
Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey. Diabetes, obesity & metabolism (2023)
Stewart B Harris, Kamel Mohammedi, Monica Bertolini, Maureen Carlyle, Valery Walker, Fang Liz Zhou, John E Anderson, Jochen Seufert
Patient and physician perspectives and experiences of basal insulin titration in type 2 diabetes in the United States: Cross-sectional surveys. Diabetes, obesity & metabolism (2023)
Stewart B Harris, Kamel Mohammedi, Monica Bertolini, John White, Valery Walker, Fang Liz Zhou, John E Anderson, Jochen Seufert
Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: a cross-sectional survey. Diabetes, obesity & metabolism (2023)
Fang Liz Zhou, Charlie J Nicholls, Lin Xie, Yuexi Wang, Neel Vaidya, Stephen H Mandy
Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting. Endocrinology, diabetes & metabolism 2 (3) (2019)
Timothy S Bailey, Jasmanda Wu, Fang Liz Zhou, Rishab A Gupta, Arjun A Menon, Paulos Berhanu, Jukka Westerbacka, John Van Vleet, Lawrence Blonde
Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3). Diabetes, obesity & metabolism 21 (11) (2019)
Timothy S Bailey, Fang Liz Zhou, Rishab A Gupta, Ronald Preblick, Vineet E Gupta, Paulos Berhanu, Lawrence Blonde
Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study. Diabetes, obesity & metabolism 21 (7) (2019)
Jeremy H Pettus, Fang Liz Zhou, Leah Shepherd, Ronald Preblick, Phillip R Hunt, Sachin Paranjape, Kellee M Miller, Steven V Edelman
Incidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World Study. Diabetes care 42 (12) (2019)
Jeremy H Pettus, Fang Liz Zhou, Leah Shepherd, Katie Mercaldi, Ronald Preblick, Phillip R Hunt, Sachin Paranjape, Kellee M Miller, Steven V Edelman
Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: A real-world study of more than 30 000 patients in a US electronic health record database. Diabetes, obesity & metabolism 22 (4) (2019)
Fang Liz Zhou, Hirotaka Watada, Yuki Tajima, Mathilde Berthelot, Dian Kang, Cyril Esnault, Yujin Shuto, Hiroshi Maegawa, Daisuke Koya
Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database. Diabetes, obesity & metabolism 21 (8) (2019)
Fang Liz Zhou, Jason Yeaw, Swapna U Karkare, Mitch DeKoven, Paulos Berhanu, Timothy Reid
Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes. BMJ open diabetes research & care 6 (1) (2018)
George E Dailey, Timothy Reid, John White, Jason Chao, Fang Liz Zhou, Sachin Paranjape, Paulos Berhanu
Improved glycaemic control and lower hypoglycaemia risk with reduced prior oral antidiabetes drug therapy in patients with type 2 diabetes treated with insulin glargine 300 U/mL. Endocrinology, diabetes & metabolism 1 (4) (2018)
Sean D Sullivan, Timothy S Bailey, Ronan Roussel, Fang Liz Zhou, Zsolt Bosnyak, Ronald Preblick, Jukka Westerbacka, Rishab A Gupta, Lawrence Blonde
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes, obesity & metabolism 20 (9) (2018)
Fang Liz Zhou, Fen Ye, Paulos Berhanu, Vineet E Gupta, Rishab A Gupta, Jennifer Sung, Jukka Westerbacka, Timothy S Bailey, Lawrence Blonde
Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. Diabetes, obesity & metabolism 20 (5) (2018)
Fang Liz Zhou, Lin Xie, Chunshen Pan, Yuexi Wang, Neel Vaidya, Fen Ye, Ronald Preblick, Stephen H Mandy
Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin. Diabetes, obesity & metabolism 20 (5) (2018)